Latest Content

A phase 3 study shows pimicotinib shrinks tumors and improves pain, stiffness and mobility in adults with unresectable tenosynovial giant cell tumors.

Paul, a liver cancer survivor, and his wife Emma share their journey of recovery, caregiving and finding balance in life after major surgeries.

Rosemary Carrera discusses her breast cancer journey, mastectomy and the personal decision to remove her implants at the Miami Breast Cancer Conference.

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact.

Dr. Joseph Mikhael, chief medical officer of the International Myeloma Foundation, provided updates from the front lines of treatment advancement.

Dr. Marleen Meyers discusses improving survival rates, the evolving needs of younger cancer survivors and how caregivers can sustain long-term support.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

A UCLA study found CAR-NKT cells eliminated endometrial tumors in models and showed stronger activity than existing immunotherapies, supporting further clinical development.

Survey shows 92% of eligible adults support coverage for colorectal cancer blood tests to improve screening access and adherence.

A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization.

At CURE, we strive to provide insight, education and inspiration for patients, survivors and caregivers at every stage of the cancer journey.